JP2011528362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528362A5 JP2011528362A5 JP2011518862A JP2011518862A JP2011528362A5 JP 2011528362 A5 JP2011528362 A5 JP 2011528362A5 JP 2011518862 A JP2011518862 A JP 2011518862A JP 2011518862 A JP2011518862 A JP 2011518862A JP 2011528362 A5 JP2011528362 A5 JP 2011528362A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- heteroaryl
- alkyl
- heterocyclyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims 151
- 125000001072 heteroaryl group Chemical group 0.000 claims 133
- 125000000217 alkyl group Chemical group 0.000 claims 131
- 125000000623 heterocyclic group Chemical group 0.000 claims 96
- 125000000753 cycloalkyl group Chemical group 0.000 claims 95
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 63
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 58
- 125000003710 aryl alkyl group Chemical group 0.000 claims 54
- 229910052739 hydrogen Inorganic materials 0.000 claims 51
- 239000001257 hydrogen Substances 0.000 claims 51
- 125000005843 halogen group Chemical group 0.000 claims 42
- 150000002431 hydrogen Chemical class 0.000 claims 41
- 125000004093 cyano group Chemical group *C#N 0.000 claims 40
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 36
- 125000003342 alkenyl group Chemical group 0.000 claims 32
- 125000001188 haloalkyl group Chemical group 0.000 claims 32
- -1 —NH 2 Chemical group 0.000 claims 32
- 125000000304 alkynyl group Chemical group 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 17
- 125000005842 heteroatom Chemical group 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 108091006027 G proteins Proteins 0.000 claims 4
- 102000030782 GTP binding Human genes 0.000 claims 4
- 108091000058 GTP-Binding Proteins 0.000 claims 4
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 4
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000003472 antidiabetic agent Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010038923 Retinopathy Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 201000008980 hyperinsulinism Diseases 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 208000031225 myocardial ischemia Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 108010010369 HIV Protease Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims 2
- 230000001708 anti-dyslipidemic effect Effects 0.000 claims 2
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 claims 2
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims 2
- 230000002946 anti-pancreatic effect Effects 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000002830 appetite depressant Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- JJLKTTCRRLHVGL-UHFFFAOYSA-L [acetyloxy(dibutyl)stannyl] acetate Chemical compound CC([O-])=O.CC([O-])=O.CCCC[Sn+2]CCCC JJLKTTCRRLHVGL-UHFFFAOYSA-L 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000002253 anti-ischaemic effect Effects 0.000 claims 1
- 230000002402 anti-lipaemic effect Effects 0.000 claims 1
- 230000003063 anti-neuropathic effect Effects 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8106908P | 2008-07-16 | 2008-07-16 | |
| US8105808P | 2008-07-16 | 2008-07-16 | |
| US8106008P | 2008-07-16 | 2008-07-16 | |
| US61/081,069 | 2008-07-16 | ||
| US61/081,060 | 2008-07-16 | ||
| US61/081,058 | 2008-07-16 | ||
| PCT/US2009/050618 WO2010009183A1 (en) | 2008-07-16 | 2009-07-15 | Pyridone and pyridazone analogues as gpr119 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011528362A JP2011528362A (ja) | 2011-11-17 |
| JP2011528362A5 true JP2011528362A5 (enExample) | 2012-08-02 |
Family
ID=41137417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518862A Pending JP2011528362A (ja) | 2008-07-16 | 2009-07-15 | Ｇｐｒ１１９モジュレーターとしてのピリドンおよびピリダゾン類似体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8372837B2 (enExample) |
| EP (1) | EP2313395B1 (enExample) |
| JP (1) | JP2011528362A (enExample) |
| CN (1) | CN102159566A (enExample) |
| AR (1) | AR073254A1 (enExample) |
| BR (1) | BRPI0915918A2 (enExample) |
| CA (1) | CA2730929A1 (enExample) |
| CY (1) | CY1113715T1 (enExample) |
| DK (1) | DK2313395T3 (enExample) |
| EA (1) | EA018268B1 (enExample) |
| ES (1) | ES2400587T3 (enExample) |
| HR (1) | HRP20130120T1 (enExample) |
| MX (1) | MX2011000394A (enExample) |
| PL (1) | PL2313395T3 (enExample) |
| PT (1) | PT2313395E (enExample) |
| SI (1) | SI2313395T1 (enExample) |
| SM (1) | SMT201300040B (enExample) |
| TW (1) | TW201006821A (enExample) |
| WO (1) | WO2010009183A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011030139A1 (en) | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| MX2012011460A (es) | 2010-04-08 | 2012-11-23 | Squibb Bristol Myers Co | Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119. |
| WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| EA201270778A1 (ru) | 2010-05-06 | 2013-04-30 | Бристол-Майерс Сквибб Компани | Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119 |
| RU2012154308A (ru) | 2010-05-17 | 2014-06-27 | Эррэй Биофарма Инк. | Пиперидинил-замещенные лактамы как модуляторы gpr119 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| DK2625177T3 (en) | 2010-10-08 | 2015-10-12 | Cadila Healthcare Ltd | New GPR 119 agonists |
| WO2012170867A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2850073B1 (en) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| CN103664795B (zh) * | 2012-09-06 | 2017-10-03 | 华东理工大学 | 哒嗪酮类化合物及其用途 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| SG11201507345RA (en) * | 2013-03-13 | 2015-10-29 | Chugai Pharmaceutical Co Ltd | Dihydropyridazine-3,5-dione derivative |
| US9499553B2 (en) | 2013-03-13 | 2016-11-22 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same |
| NO2986357T3 (enExample) | 2013-04-18 | 2018-07-14 | ||
| CA2910131A1 (en) * | 2013-04-25 | 2014-10-30 | Yuhan Corporation | Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same |
| CN106459042B (zh) | 2014-04-02 | 2019-06-28 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
| CN104370806B (zh) * | 2014-06-17 | 2017-07-07 | 中国海洋大学 | 一种吡啶酮生物碱类化合物及其制备方法和用途 |
| EA202092269A1 (ru) * | 2018-03-23 | 2020-12-14 | Кармот Терапьютикс, Инк. | Модуляторы сопряженных с g-белком рецепторов |
| IL277978B2 (en) * | 2018-04-25 | 2024-07-01 | Bayer Ag | Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides |
| SG11202102624SA (en) | 2018-09-27 | 2021-04-29 | Fmc Corp | Intermediates for preparing herbicidal pyridazinones |
| CN110845426A (zh) * | 2019-11-29 | 2020-02-28 | 都创(上海)医药科技有限公司 | 一种2-氯-5-氰基嘧啶化合物制备方法 |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| WO2021231630A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| CN117980325A (zh) | 2021-05-13 | 2024-05-03 | 卡莫特治疗学股份有限公司 | G-蛋白偶联受体的调节剂 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826643A (en) | 1967-08-07 | 1974-07-30 | American Cyanamid Co | Method of controlling undesirable plant species using 3-nitropyridines |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US6566384B1 (en) | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| ATE416772T1 (de) | 1998-07-06 | 2008-12-15 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
| AU3127900A (en) | 1998-12-23 | 2000-07-31 | Du Pont Pharmaceuticals Company | Thrombin or factor xa inhibitors |
| WO2002002519A2 (en) | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | THROMBIN OR FACTOR Xa INHIBITORS |
| DE60125227T2 (de) | 2000-12-01 | 2007-09-20 | Astellas Pharma Inc. | Verfahren zum screening von diabetes-heilverfahren |
| US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| CA2488635C (en) * | 2002-06-12 | 2012-10-23 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
| KR101078098B1 (ko) | 2003-01-14 | 2011-10-28 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료 |
| CA2515963A1 (en) | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| CN100509798C (zh) * | 2003-07-11 | 2009-07-08 | 艾尼纳制药公司 | 作为新陈代谢调节剂的三取代芳基和杂芳基衍生物以及预防和治疗与其相关之病症 |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| SG144942A1 (en) * | 2003-07-14 | 2008-08-28 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| AR045697A1 (es) * | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| US20070088163A1 (en) | 2003-09-12 | 2007-04-19 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
| ATE519495T1 (de) | 2004-03-17 | 2011-08-15 | 7Tm Pharma As | Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe |
| DK1756096T3 (da) | 2004-05-03 | 2009-10-26 | Hoffmann La Roche | Indolylderivater som lever-X-receptormodulatorer |
| HRP20090093T3 (en) * | 2004-06-04 | 2009-03-31 | Arena Pharmaceuticals Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| CA2612187C (en) | 2005-06-23 | 2013-05-07 | Emory University | Stereoselective synthesis of amino acid analogs for tumor imaging |
| US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| CA2661371A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyrimidine compounds for treating gpr119 related disorders |
| WO2008137435A1 (en) * | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| EA018709B1 (ru) * | 2007-07-17 | 2013-10-30 | Бристол-Маерс Сквибб Компани | Пиридоновые агонисты сопряженного с g-белком рецептора gpr119 |
| JPWO2010074090A1 (ja) * | 2008-12-25 | 2012-06-21 | 日産化学工業株式会社 | ピリダジン−３（２ｈ）−オン化合物塩酸塩の結晶及びその製造方法 |
| MX2012011460A (es) * | 2010-04-08 | 2012-11-23 | Squibb Bristol Myers Co | Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119. |
-
2009
- 2009-07-10 TW TW098123477A patent/TW201006821A/zh unknown
- 2009-07-15 WO PCT/US2009/050618 patent/WO2010009183A1/en not_active Ceased
- 2009-07-15 CN CN2009801362083A patent/CN102159566A/zh active Pending
- 2009-07-15 PL PL09790426T patent/PL2313395T3/pl unknown
- 2009-07-15 EP EP09790426A patent/EP2313395B1/en not_active Not-in-force
- 2009-07-15 MX MX2011000394A patent/MX2011000394A/es active IP Right Grant
- 2009-07-15 ES ES09790426T patent/ES2400587T3/es active Active
- 2009-07-15 CA CA2730929A patent/CA2730929A1/en not_active Abandoned
- 2009-07-15 AR ARP090102687A patent/AR073254A1/es not_active Application Discontinuation
- 2009-07-15 US US13/003,914 patent/US8372837B2/en active Active
- 2009-07-15 DK DK09790426.2T patent/DK2313395T3/da active
- 2009-07-15 JP JP2011518862A patent/JP2011528362A/ja active Pending
- 2009-07-15 SI SI200930537T patent/SI2313395T1/sl unknown
- 2009-07-15 BR BRPI0915918A patent/BRPI0915918A2/pt not_active IP Right Cessation
- 2009-07-15 HR HRP20130120AT patent/HRP20130120T1/hr unknown
- 2009-07-15 EA EA201100210A patent/EA018268B1/ru not_active IP Right Cessation
- 2009-07-15 PT PT97904262T patent/PT2313395E/pt unknown
-
2013
- 2013-01-18 US US13/744,604 patent/US20130131074A1/en not_active Abandoned
- 2013-02-22 CY CY20131100168T patent/CY1113715T1/el unknown
- 2013-04-03 SM SM201300040T patent/SMT201300040B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528362A5 (enExample) | ||
| JP2010533726A5 (enExample) | ||
| JP2010526145A5 (enExample) | ||
| JP2010529203A5 (enExample) | ||
| JP2014518853A5 (enExample) | ||
| JP6907173B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| CA2488592A1 (en) | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | |
| HRP20110806T1 (hr) | Agonisti piridon gpr119 g protein-vezanih receptora | |
| JP2008513504A5 (enExample) | ||
| KR20190026687A (ko) | 간 섬유화 치료 방법 | |
| JP2019059951A (ja) | グリコサミノグリカン誘導体及びその製造方法 | |
| JP2018518537A5 (enExample) | ||
| JP2019510039A5 (enExample) | ||
| CA2798610A1 (en) | Bicyclic heteroaryl compounds as gpr119 modulators | |
| TW200621249A (en) | Substituted amide beta secretase inhibitors | |
| CA2537127A1 (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
| JP2010514829A5 (enExample) | ||
| RU2007142336A (ru) | Арилалкилзамещенные производные кислот и их применение | |
| BG105954A (en) | Oxamic acids and derivatives as thyroid receptor ligands | |
| RU2005139525A (ru) | N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы | |
| JP2008521829A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| RU97102362A (ru) | Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола | |
| US20140323523A1 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
| CA2545092A1 (en) | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |